feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Kansas City airport lockdown

trending

Barmore faces assault charge

trending

Vanderbilt ReliaQuest Bowl opt-outs

trending

Wembanyama leaves game injured

trending

Lanning calls for CFB changes

trending

Warriors face Hornets Wednesday

trending

Sabres beat Stars, win streak

trending

Duke faces Arizona State

trending

Michigan football without 15 players

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Miracle Drug Helps Boy Walk After Rare Genetic Disorder

Miracle Drug Helps Boy Walk After Rare Genetic Disorder

1 Jan

•

Summary

  • A 5-year-old boy with SMA can now walk independently after treatment.
  • He received Zolgensma, the world's most expensive drug at $2.4 million.
  • The gene therapy was administered in 2021 through the UK's NHS.
Miracle Drug Helps Boy Walk After Rare Genetic Disorder

Edward, a 5-year-old boy from Essex, UK, has achieved remarkable milestones, including walking independently, after receiving a revolutionary gene therapy. Diagnosed with spinal muscular atrophy (SMA) at two months old, Edward was treated in 2021 with Zolgensma, a drug costing approximately $2.4 million per dose. This treatment, administered through the UK's National Health Service, has significantly improved his quality of life.

His mother shared that Edward has made incredible progress, overcoming challenges associated with SMA. Beyond walking, he enjoys swimming and participating in activities like jet-skiing, demonstrating a quality of life previously considered unattainable for children with his condition. Despite needing a wheelchair and undergoing a double hip replacement, his spirit remains high.

Professor James Palmer of NHS England highlighted Edward as one of over 150 children benefiting from this one-shot treatment. This success story fuels optimism for future advancements in treating genetic disorders, with ongoing private care supporting Edward's continued development and well-being.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
SMA is a rare, often fatal genetic disease causing paralysis, muscle weakness, and progressive loss of movement.
The gene therapy, Zolgensma, cost approximately $2.4 million per dose, making it the world's most expensive drug.
Yes, Edward was one of the first children in England to receive Zolgensma through the National Health Service (NHS) in 2021.

Read more news on

Healthside-arrow

You may also like

Nurse's 'Burning Liquid' Attack on Paralyzed Patient

15 Dec, 2025 • 67 reads

article image

Breast Cancer: UK Cases & Deaths to Skyrocket by 2050

7 Dec, 2025 • 118 reads

article image

Two Children, Two Futures: The Power of Early SMA Test

30 Nov, 2025 • 120 reads

article image

NHS Failing Fibromyalgia Sufferers, Study Finds

28 Nov, 2025 • 109 reads

article image

NHS Resilient: 95% Care Maintained Amidst Doctor Strikes

23 Nov, 2025 • 199 reads

article image